Neumora Therapeutics posts a DCF fair value of $1.1. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Markets price NMRA on many factors — sentiment, liquidity, and near-term news — while DCF focuses on long-run cash flows. The current fair-value estimate of $1.1 sits 64.4% above the live price. Large gaps can highlight opportunity or model risk; the charts on this page help you see how the estimate has moved over time.

Context for NMRA's DCF fair value usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Neumora Therapeutics's other metric pages and overview cover the third.